Articles producció científica> Medicina i Cirurgia

Underlying heart diseases and acute COVID-19 outcomes

  • Identification data

    Identifier: imarina:9207264
    Authors:
    Nunez-Gil, Ivan J.Fernandez-Ortiz, AntonioMaroud Eid, CharbelHuang, JiaRomero, RodolfoManuel Becerra-Munoz, VictorUribarri, AitorFeltes, GiselaTrabatoni, DanielaFernandez-Rozas, InmaculadaViana-Llamas, Maria C.Pepe, MartinoCerrato, EnricoBertaina, MaurizioAstrua, Thamar CapelAlfonso, EmilioCastro-Mejia, Alex F.Raposeiras-Roubin, SergioD'Ascenzo, FabrizioEspejo Paeres, CarolinaSignes-Costa, JaimeBardaji, AlfredoFernandez-Perez, CristinaMarin, FranciscoFabregat-Andres, OscarAkin, IbrahimEstrada, VicenteMacaya, CarlosHope COVID-19 Investigators
    Abstract:
    Background: The presence of any underlying heart condition could influence outcomes during the coronavirus disease 2019 (COVID-19). Methods: The registry HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19, NCT04334291) is an international ambispective study, enrolling COVID-19 patients discharged from hospital, dead or alive. Results: HOPE enrolled 2798 patients from 35 centers in 7 countries. Median age was 67 years (IQR: 53.0-78.0), and most were male (59.5%). A relevant heart disease was present in 682 (24%) cases. These were older, more frequently male, with higher overall burden of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, smoking habit, obesity) and other comorbidities such renal failure, lung, cerebrovascular disease and oncologic antecedents (p < 0.01, for all). The heart cohort received more corticoids (28.9% vs. 20.4%, p < 0.001), antibiotics, but less hydroxychloroquine, antivirals or tocilizumab. Considering the epidemiologic profile, a previous heart condition was independently related with short-term mortality in the Cox multivariate analysis (1.62; 95% CI 1.29-2.03; p < 0.001). Moreover, heart patients needed more respiratory, circulatory support, and presented more in-hospital events, such heart failure, renal failure, respiratory insufficiency, sepsis, systemic infammatory response syndrome and clinically relevant bleedings (all, p < 0.001), and mortality (39.7% vs. 15.5%; p < 0.001). Conclusions: An underlying heart disease is an adverse prognostic factor for patients suffering COVID-19. Its presence could be related with different clinical drug management and would benefit from maintaining treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers during in-hospital stay.
  • Others:

    Author, as appears in the article.: Nunez-Gil, Ivan J.; Fernandez-Ortiz, Antonio; Maroud Eid, Charbel; Huang, Jia; Romero, Rodolfo; Manuel Becerra-Munoz, Victor; Uribarri, Aitor; Feltes, Gisela; Trabatoni, Daniela; Fernandez-Rozas, Inmaculada; Viana-Llamas, Maria C.; Pepe, Martino; Cerrato, Enrico; Bertaina, Maurizio; Astrua, Thamar Capel; Alfonso, Emilio; Castro-Mejia, Alex F.; Raposeiras-Roubin, Sergio; D'Ascenzo, Fabrizio; Espejo Paeres, Carolina; Signes-Costa, Jaime; Bardaji, Alfredo; Fernandez-Perez, Cristina; Marin, Francisco; Fabregat-Andres, Oscar; Akin, Ibrahim; Estrada, Vicente; Macaya, Carlos;Hope COVID-19 Investigators
    Department: Medicina i Cirurgia
    URV's Author/s: Bardají Ruiz, Alfredo
    Keywords: Registry Prognosis Myocardial-infarction Mortality Heart disease Covid-19 Cardiovascular-disease Cardiology Ace2 expression
    Abstract: Background: The presence of any underlying heart condition could influence outcomes during the coronavirus disease 2019 (COVID-19). Methods: The registry HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19, NCT04334291) is an international ambispective study, enrolling COVID-19 patients discharged from hospital, dead or alive. Results: HOPE enrolled 2798 patients from 35 centers in 7 countries. Median age was 67 years (IQR: 53.0-78.0), and most were male (59.5%). A relevant heart disease was present in 682 (24%) cases. These were older, more frequently male, with higher overall burden of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, smoking habit, obesity) and other comorbidities such renal failure, lung, cerebrovascular disease and oncologic antecedents (p < 0.01, for all). The heart cohort received more corticoids (28.9% vs. 20.4%, p < 0.001), antibiotics, but less hydroxychloroquine, antivirals or tocilizumab. Considering the epidemiologic profile, a previous heart condition was independently related with short-term mortality in the Cox multivariate analysis (1.62; 95% CI 1.29-2.03; p < 0.001). Moreover, heart patients needed more respiratory, circulatory support, and presented more in-hospital events, such heart failure, renal failure, respiratory insufficiency, sepsis, systemic infammatory response syndrome and clinically relevant bleedings (all, p < 0.001), and mortality (39.7% vs. 15.5%; p < 0.001). Conclusions: An underlying heart disease is an adverse prognostic factor for patients suffering COVID-19. Its presence could be related with different clinical drug management and would benefit from maintaining treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers during in-hospital stay.
    Thematic Areas: Saúde coletiva Medicine (miscellaneous) Medicina iii Medicina ii Medicina i Interdisciplinar General medicine Educação física Ciências biológicas ii Cardiology and cardiovascular medicine Cardiac & cardiovascular systems
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: alfredo.bardaji@urv.cat
    Author identifier: 0000-0003-1900-6974
    Record's date: 2024-07-27
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://pubmed.ncbi.nlm.nih.gov/33346365/
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Cardiology Journal. 28 (2): 202-214
    APA: Nunez-Gil, Ivan J.; Fernandez-Ortiz, Antonio; Maroud Eid, Charbel; Huang, Jia; Romero, Rodolfo; Manuel Becerra-Munoz, Victor; Uribarri, Aitor; Feltes, (2021). Underlying heart diseases and acute COVID-19 outcomes. Cardiology Journal, 28(2), 202-214. DOI: 10.5603/CJ.a2020.0183
    Article's DOI: 10.5603/CJ.a2020.0183
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2021
    Publication Type: Journal Publications
  • Keywords:

    Cardiac & Cardiovascular Systems,Cardiology and Cardiovascular Medicine,Medicine (Miscellaneous)
    Registry
    Prognosis
    Myocardial-infarction
    Mortality
    Heart disease
    Covid-19
    Cardiovascular-disease
    Cardiology
    Ace2 expression
    Saúde coletiva
    Medicine (miscellaneous)
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    General medicine
    Educação física
    Ciências biológicas ii
    Cardiology and cardiovascular medicine
    Cardiac & cardiovascular systems
  • Documents:

  • Cerca a google

    Search to google scholar